转移性去势抵抗性前列腺癌患者循环肿瘤细胞中BRCA2拷贝数缺失与基因组不稳定性分析
本研究对138例进展期转移性去势抵抗性前列腺癌(mCRPC)患者的循环肿瘤细胞(CTC)行单细胞浅层全基因组测序(sWGS),并与同期肿瘤活检比较。CTC sWGS生成拷贝数谱的比例与活检样本相似(83% vs 78%,p=0.23),且高于骨活检(79% vs 50%;p=0.009)。CTC sWGS在≥1和≥2 CTC阈值下检出的BRCA2缺失均多于组织(42% vs 16%,p<0.001;27% vs 16%,p=0.028),CTC BRCA2缺失与更高的基因组不稳定性相关(1.4倍大尺度转换差异,95%CI 1.2-1.6;p<0.001)。
要点
- CTC sWGS生成拷贝数谱的比例与活检样本相似(83% vs 78%,p=0.23),高于骨活检(79% vs 50%;p=0.009)。
- CTC sWGS在≥1和≥2 CTC阈值下检出BRCA2缺失均多于组织(42% vs 16%,p<0.001;27% vs 16%,p=0.028)。
- CTC BRCA2缺失与更高的基因组不稳定性相关(单变量1.4倍大尺度转换差异,95%CI 1.2-1.6;p<0.001)。
核心结论
- CTC sWGS可可靠生成拷贝数谱,检出大多数组织确认的BRCA2缺失及「仅CTC」缺失,BRCA2缺失得到基因组不稳定性升高的支持。
研究设计与样本
- 分析进展期mCRPC患者中与临床测序肿瘤活检同期采集的CTC样本,共识别138例有同期CTC和活检样本的患者。
主要发现
- CTC sWGS生成拷贝数谱的患者比例与活检样本相似(83% vs 78%,p=0.23),但高于骨活检(79% vs 50%;p=0.009)。
- CTC sWGS在≥1 CTC阈值检出BRCA2缺失的患者多于组织(42% vs 16%;p<0.001),在≥2 CTC阈值亦多于组织(27% vs 16%;p=0.028)。
- 使用样本水平复合z评分时,CTC中BRCA2缺失总体患病率未增加(p=0.4),但显著高于骨样本中低于预期的患病率(21% vs 3%,p=0.014)。
- CTC BRCA2缺失的阳性/阴性预测值在≥1 CTC阈值下为89%/96%,在复合z评分下为67%/92%。
- CTC BRCA2缺失与更高的基因组不稳定性相关:单变量分析1.4倍大尺度转换差异(95%CI 1.2-1.6;p<0.001),多变量分析1.4倍差异(95%CI 1.2-1.6;p<0.001)。
关键数值与推荐
- CTC sWGS在≥1 CTC阈值检出BRCA2缺失42% vs 组织16%(p<0.001),≥2 CTC阈值27% vs 16%(p=0.028)。
- CTC BRCA2缺失阳性/阴性预测值:≥1 CTC阈值89%/96%,复合z评分67%/92%。
- CTC BRCA2缺失与基因组不稳定性关联:单变量1.4倍(95%CI 1.2-1.6;p<0.001),多变量1.4倍(95%CI 1.2-1.6;p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BRCA2 alterations predict for a response to poly-ADP-ribose polymerase inhibition in metastatic castration-resistant prostate cancer (mCRPC). However, detection is hindered by insufficient tumor tissue and low sensitivity of cell-free DNA for detecting copy number loss. OBJECTIVE: To evaluate the BRCA2 loss detection using single-cell, shallow whole-genome sequencing (sWGS) of circulating tumor cells (CTCs) in patients with mCRPC. DESIGN, SETTING, AND PARTICIPANTS: We analyzed CTC samples collected concurrently with tumor biopsies intended for clinical sequencing in patients with progressing mCRPC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Differences in proportions were evaluated using the chi-square test. Correlations between assays were analyzed in linear regression models. Associations between alterations and genomic instability were assessed on the single-cell level using mixed-effect negative binomial models. RESULTS AND LIMITATIONS: We identified 138 patients with concurrent CTC and biopsy samples. CTC sWGS generated copy number profiles in a similar proportion of patients to biopsy samples (83% vs 78%, p = 0.23), but was more effective than bone biopsies (79% vs 50%; p = 0.009). CTC sWGS detected BRCA2 loss in more patients than tissue at the ≥1 (42% vs 16%; p < 0.001) and ≥2 (27% vs 16%; p = 0.028) CTC thresholds. The overall prevalence of BRCA2 loss was not increased in CTCs using sample-level composite z scores (p = 0.4), but was significantly increased compared with a lower-than-expected prevalence in bone samples (21% vs 3%, p = 0.014). Positive/negative predictive values for CTC BRCA2 loss were 89%/96% using the ≥1 CTC threshold and 67%/92% using the composite z score. CTC BRCA2 loss was associated with higher genomic instability in univariate (1.4-fold large-scale transition difference, 95% confidence interval [CI]: 1.2-1.6; p < 0.001) and multivariable analysis (1.4-fold difference, 95% CI: 1.2-1.6; p < 0.001). CONCLUSIONS: Copy number profiles can reliably be generated using CTC sWGS, which detected a majority of tissue-confirmed BRCA2 loss and "CTC-only" losses. BRCA2 losses were supported by increases in genomic instability. PATIENT SUMMARY: Current testing strategies have limitations in their ability to detect BRCA2 loss, a relatively common alteration in prostate cancer that is used to identify patients who may benefit from targeted therapy. In this paper, we evaluated whether we could detect BRCA2 loss in individual tumor cells isolated from patient blood samples and found this method to be suitable for further analysis.
引用
- Barnett ES, Schultz N, Stopsack KH, et al. Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2022. PMID: 36123219. doi:10.1016/j.eururo.2022.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。